Watch our animation in Full
INTRODUCING OXIMO
A Novel Therapeutic Approach for Herpes
Watch our animation in Full
INTRODUCING OXIMO
A Novel Therapeutic Approach for Herpes
Watch our animation in Full
INTRODUCING OXIMO
A Novel Therapeutic Approach for Herpes
MISSION
We are dedicated to delivering efficient and reliable solutions for the treatment of patients infected with Herpes Simplex Virus, with a particular focus on conditions that cause the most significant medical, psychological, and social distress.
MISSION
We are dedicated to delivering efficient and reliable solutions for the treatment of patients infected with Herpes Simplex Virus, with a particular focus on conditions that cause the most significant medical, psychological, and social distress.
MISSION
We are dedicated to delivering efficient and reliable solutions for the treatment of patients infected with Herpes Simplex Virus, with a particular focus on conditions that cause the most significant medical, psychological, and social distress.
A NOVEL PEROXOMOLYBDATE-BASED ANTIVIRAL PLATFORM
Our invention leverages controlled oxidative biology - an antiviral approach supported by established clinical experience with reactive oxygen species across multiple therapeutic platforms.
Directly targeting HSV
Oximo inactivates HSV both extracellularly and intracellularly by generating specific Reactive Oxygen Species (ROS), disrupting viral particles and halting replication, ensuring a comprehensive antiviral activity throughout the infection pathway.
Blocking HSV entry
A NOVEL PEROXOMOLYBDATE-BASED ANTIVIRAL PLATFORM
Our invention leverages controlled oxidative biology - an antiviral approach supported by established clinical experience with reactive oxygen species across multiple therapeutic platforms.
Directly targeting HSV
Oximo inactivates HSV both extracellularly and intracellularly by generating specific Reactive Oxygen Species (ROS), disrupting viral particles and halting replication, ensuring a comprehensive antiviral activity throughout the infection pathway.
Blocking HSV entry
A NOVEL PEROXOMOLYBDATE-BASED ANTIVIRAL PLATFORM
Our invention leverages controlled oxidative biology - an antiviral approach supported by established clinical experience with reactive oxygen species across multiple therapeutic platforms.
Directly targeting HSV
Oximo inactivates HSV both extracellularly and intracellularly by generating specific Reactive Oxygen Species (ROS), disrupting viral particles and halting replication, ensuring a comprehensive antiviral activity throughout the infection pathway.
Blocking HSV entry
CONTACT
First topical drug candidate designed to intervene at the early stage of recurrent herpes episodes, with the objective of preventing lesions development and accelerating return to normal skin
CONTACT
First topical drug candidate designed to intervene at the early stage of recurrent herpes episodes, with the objective of preventing lesions development and accelerating return to normal skin
CONTACT
First topical drug candidate designed to intervene at the early stage of recurrent herpes episodes, with the objective of preventing lesions development and accelerating return to normal skin
NEWS
Latest Updates from OXYMO
NEWS
Latest Updates from OXYMO
NEWS